Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: Treatment with low-dose arabinosyl cytosine

Journal of Pediatric Hematology/Oncology

Volumn 18, Issue 1, 1996, Pages 59-62

  Tchernia, Gil ^a,c   Lejeune, Françoise ^b   Boccara, Jean Françoise ^b   Denavit, Marie Françoise ^b   Dommergues, Jean Paul ^a   Bernaudin, Françoise ^b  

^a Depts of Hematology and Pediatrics   (France)

^b Department of Pediatrics ^*  (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

Arabinosyl cytosine; Down syndrome; Megakaryoblastic leukemia

Indexed keywords

CYTARABINE;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOSE RESPONSE; DOWN SYNDROME; ERYTHROLEUKEMIA; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CHILD, PRESCHOOL; CYTARABINE; DISEASE-FREE SURVIVAL; DOWN SYNDROME; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; MALE; REMISSION INDUCTION;

EID: 0030031345     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199602000-00011     Document Type: Article

References (28)

1. Simon JH, Tebbi CK, Freeman AI, et al. Acute megakaryoblastic leukemia associated with mosaic Down's syndrome. Cancer 1987;60:2515-20.
2. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol 1992;9:139-49.
3. Kojima S, Matsuyama T, Sato T, et al. Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction. Blood 1990;76:2348-53.
4. Coulombel L, Derycke M. Villeval JL, et al. Characterization of the blast cell population in two neonates with Down's syndrome and transient myeloproliferative disorder. Br J Haematol 1987;66:69-76.
5. Villeval JL, Cramer P, Lemoine F, et al. Phenotype of early erythroblastic leukemias. Blood 1986;68:1167-74.
6. Sartori PCE, Darbyshire PJ. Transient myeloproliferative disorder in Down's syndrome: three cases with megakaryocytic markers. Pediatr Hematol Oncol 1991;87:139-45.
7. Bennett JM, Catovsky DC, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:460-2.
8. Griffin J, Munroe D, Major P, Kufe D. Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis. Exp Hematol 1982;10:774-81.
9. Castaigne S, Daniel MT, Tilly H, et al. Does treatment with Ara-C in low-dosage cause differentiation of leukemic cells? Blood 1983;62:85-6.
10. Mittermüller J, Kolb HJ, Gerhartz HH, Wilmanns W. In vivo differentiation of leukaemic blasts and effect of low-dose Ara-C in a marrow grafted patient with leukaemic relapse. Br J Haematol 1986;62:757-62.
11. Tertian G, Tchernia G, Léonard C. et al. Low-dose arabinosyl cytosine therapy of AML can be effective after failure of high or conventional doses. Nouv Rev Fr Hematol 1989;31:311-3.
12. Desforges JF. Cytarabine: low dose, high dose, no dose? N Engl J Med 1983;309:1637-38.
13. Weisdorf D, Perri RT, Arthur DC, et al. In vitro correlates of low-dose Ara-C efficacy: clinical, cytogenetic, and bone marrow culture analysis. Am J Hematol 1987;25:45-53.
14. Zipursky A, Rivard G, Freedman MH. Differentiation of leukemic megakaryoblasts in Down syndrome. Blood 1992;80:32a.
15. Huang MJ, Li CY, Nichols WL, et al. Acute leukemia with megakaryocytic differentiation: a study of 12 cases identified immunocytochemically. Blood 1984;64:427-39.
16. Ruiz-Argüelles GJ, Marin-Lopez A, Lobato-Mendizabal E, et al. Acute megakaryoblastic leukemia: a prospective study of its identification and treatment. Br J Haematol 1986;62:55-63.
17. Cairney AEL, McKenna R, Arthur DC, et al. Acute megakaryoblastic leukemia in children. Br J Haematol 1986;63:541-54.
18. Garel D, Mielot F, Gaulard P, et al. Acute megakaryocytic leukemia (AMKL) with major myelofibrosis in an infant. Diagnosis by liver biopsy and response to treatment. Nouv Rev Fr Hematol 1991;33:5-8.
19. Ruiz-Arguelles GJ, Lobato-Mendizabal E, San Miguel JF, et al. Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentric study. Br J Haematol 1992;82:671-5.
20. Blatt J, Albo V, Prin W, et al. Excessive chemotherapy related myelotoxicity in children with Down syndrome and acute lymphoblastic leukaemia. Lancet 1986;2:914.
21. Garre ML, Relling MV, Kalwinski D, et al. Pharmacokinetics and toxicity of methotrexate in children with Down's syndrome and ALL. J Pediatr 1987;11:606-12.
22. Levitt GA, Stiller CA, Chessells JM. Prognosis of Down's syndrome with acute leukaemia. Arch Dis Child 1990;65:212-6.
23. Arenson EB, Forde MD. Bone marrow transplantation for acute leukemia and Down syndrome: report of a successful case and results of a national survey. J Pediatr 1989;114:69-72.
24. Churchill LR. Bone marrow transplantation, physician bias, and Down syndrome: ethical reflection. J Pediatr 1989;114:87-8.
25. Ravindranath Y, Abella E, Krischer JP, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992;80:2210-4.
26. Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res 1994;18:163-71.
27. Dewald GW, Diez-Martin JL, Steffen SL, et al. Hematologic disorders in 13 patients with acquired trisomy 21 and 13 individuals with Down syndrome. Am J Med Genet Suppl 1990;7:247-50.
28. Eguchi M, Ozawa T, Sakakibara H, et al. Ultrastructural and ultracytochemical differences between megakaryoblastic leukemia in children and adults. Cancer 1992;70:451-8.